tPA using both eukaryotic (CHO) and prokaryotic cells ( E.coli).
This assignment is based on the paper by Datar et al. attached to the Week 3 content. This is an old paper (1993) but it is very useful for illustrating some important points in biotechnology processes and reinforcing some of the material we have discussed. The decision on expression systems is still an important one, as discussed in this article. When this paper was written many promising drugs were not making it to market because they could not be synthesized cost-effectively in bulk (the same is still true today in many cases). Therefore process economics plays an important role in the drug development process. Often there are multiple pathways to producing a drug target and it is the responsibility of the process development team to identify the fixed and variable costs associated with each pathway in the context of the scale of production expected when the drug is released on the market. See link to paper in Week 3 content Details Read the Datar et al. which is a case study describing the process economics of the production of tPA using both eukaryotic cells (CHO) and prokaryotic cells (E. coli). Write a concise and articulate report using prose (400-600 words; not in outline format) addressing the following questions: Mammalian culture is generally believed to be more expensive to operate than prokaryotic culture. What made this case study unique was the opposite result. In your opinion, what are the main reasons why recombinant tPA cost less to manufacture from CHO cells than that from E. coli? What are the bottlenecks in production of CHO-tPA and Bacterial tPA? Why was the equipment cost of bacterial tPA much higher than that of CHO-tPA? What are the lessons you have learned from this case study on tPA bioprocessing? How can they be applied to current biopharmaceuticals?
tPA using both eukaryotic (CHO) and prokaryotic cells ( E.coli)